Internationale Partnersuche

Innovation & Technologie Angebot

A range of novel hybridoma, monoclonal and polyclonal antibodies available for licencing

Country of Origin: United Kingdom
Reference Number: TOUK20201216002
Publication Date: 6 January 2021

Summary

A UK non-profit organisation can source and supply a range of antibodies, relating to a variety of life science research areas including, but not limited to, oncology, immunology, and neurobiology. The antibodies are available to life science tool providers and researchers in biotech, pharma and academic institutes via licensing agreement.

Description

A UK non-profit organisation can source and supply a range of antibodies, to life science tool providers and researchers in biotech, pharma and academic institutes. 



They have access to a range of novel hybridoma, monoclonal and polyclonal antibodies, from over 150 institutes worldwide, relating to a variety of life science research areas including oncology, immunology, neurobiology, and cell-type or organelle markers.



The diverse and comprehensive portfolio allows researchers to source antibodies ideally suited to their needs. Life science tool providers can access these antibodies via an exclusive or non-exclusive licensing agreement to expand their commercial portfolios.

Advantages and Innovations

Over 2700 hybridoma, monoclonal, and polyclonal antibodies available in the portfolio, with new antibodies added weekly providing valuable revenue to researchers who have invented the antibodies.



Some of the most popular antibodies include:

Anti-CD3 (cluster of differentiation) [UCH-T1], Anti-CD45RO [UCH-L1], Anti-Integrin aM [ICRF44], Anti-FCGR1 (Fc gamma receptors) [10.1], Anti-PTPRC [HLe-1(2D1)], Anti-cMyc [9E10], Anti-PECAM1 [JC70], brainbow polyclonal antibodies and Anti-G quadruplex recombinant [BG4].

Stage Of Development

Already on the market

Requested partner

Type: Industry or academia

Activity of partner: Life science researchers

Specific role of partner sought: The licensing of antibodies for use in their research.